Outcomes of Pharmaceutical Outcomes Research: Impact of Studies Funded

References

 

1. Tunis S, Stryer D. The Outcome of Outcomes Research at AHCPR. Rockville, (MD): U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; Nov 1998.

 

2. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. Outcomes of Pharmaceutical Therapy Program (OPT) Update. AHRQ Publication No. 01R001. Rockville (MD): Agency for Healthcare Research and Quality; Nov 2000.

 

3. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996 Feb;312(7027):338-45.

 

4. PI Interview (Joseph Lau), September 2000.

 

5. Lau J, Chalmers TC. Should intravenous magnesium be given to patients with acute myocardial infarction? [abstract]. Clin Res 1994;42(2):290A.

 

6. Lau J. Comparative outcomes of ambulatory pharmaceutical agents: Final report 1997. Rockville (MD):1998. Agency for Health Care Policy and Research; NTIS Accession No. PB 98-115405.

 

7. Chalmers TC, Lau J. Meta-analysis stimulus for changes in clinical trials. Stat Methods Med Res 1993;2(2):161-72.

 

8. Giatras I, Lau J, Levey AS. Effect of angiotensin-convert-ing enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127(5):337-45.

 

9. Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124(7):627-32.

 

10. de Ferranti SD, Ioannidis JP, Lau J, et al. Are amoxcyilin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. BMJ 1998; 317(7159):632-7.

 

11. Ioannidis JP, Cappelleri JC, Lau J, et al. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996;10(3):255-62.

 

12. Wynia MK, Ioannidis JP, Lau J. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates. AIDS 1998 Jul;30;12(11):1317-25.

 

13. Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol 1997;50(10):1089-98.

 

14. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994;121(5):355-62.

 

15. Tierney WM, Takesue BY, Vargo DL, et al. Using electronic medical records to predict mortality in primary care patients with heart disease: prognostic power and pathophysiologic implications. J Gen Intern Med 1996;11(2):83-91.

 

16. Tierney WM. Computer-based prospective drug utilization review: Abstract, executive summary, and final report. 1998. Rockville (MD):1998. Agency for Health Care Policy and Research; NTIS Accession No. PB 98-139751.

 

17. Tierney WM, Overhage JM, Takesue BY, et al. Computerizing guidelines to improve care and patient outcomes: the example of heart failure. J Am Med Inform Assoc 1995;2(5):316-22.

 

18. Murray MD, Loos B, Tu W, et al. Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions. Am J Health Syst Pharm 1999;56(3):225-32.

 

19. PI Interview (William Tierney), November 2000.

 

20. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37(5):469-78.

 

21. PI Interview (William Tierney), September 2000.

 

22. Murray MD, Harris LE, Overhage JM, et al. Association between medication possession ratio and reported compliance [abstract]. J Gen Intern Med 1997;12(suppl.):77.

 

23. Murray MD, Rupp MT, Overhage JM, et al. Multidimensional work sampling in an outpatient pharmacy. Pharm Pract Manag Q 1995;15(3):44-56.

 

24. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis—Part I: Osteoarthritis of the hip. Arthritis Rheum 1995;38(11):1535-40.

 

25. Griffin MR, Brandt KD, Liang MH, et al. Practical management of osteoarthritis. Integration of pharmacologic and nonpharmacologic measures. Arch Fam Med 1995;4(12):1049-55.

 

26. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med 1995;332(24):1612-17.

 

27. Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11(8):461-69.

 

28. Ray WA. Policy and program analysis using administrative databases. Ann Intern Med 1997;127(8, pt. 2):712-18.

 

29. Agency for Health Care Policy and Research. Selected greatest hits of outcomes research at AHCPR. Rockville (MD):l999. The Agency: unpublished document.

 

30. Berman S. Outcomes associated with therapy for otitis media: Final report 1997. Rockville (MD):1998. Agency for Health Care Policy and Research; NTIS Accession No. PB 98-119480.

 

31. Roark R, Petrofski J, Berson E, et al. Practice variations among pediatricians and family physicians in the management of otitis media. Arch Pediatr Adolesc Med 1995;149:839-44.

 

32. Berman S, Byrns P, Roark R, et al. The effect of having a Medicaid primary care provider on the utilization of otitis related services [abstract]. Arch Pediatr Adolesc Med 1995;149(suppl.).

 

33. Berman S, Byrns PJ, Bondy J, et al. Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric Medicaid population. Pediatrics 1997;100(4):585-92.

 

34. Bondy J, Berman S, Glazner J, et al. Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort. Pediatrics 2000 June;105(6):E72.

 

35. Berman S, Wu K, Roark R. Management of otitis media media with effusion with prednisone in combination with an antibiotic. International Pediatrics 1999;14(4):30-33.

 

36. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998;279(17):1358-63.

 

37. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279(17):1351-57.

 

38. Gillman MW, Ross-Degnan D, McLaughlin TJ, et al. Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction. J Am Geriatr Soc 1999;47(5):512-17.

 

39. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277(2):115-21.

 

40. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996;10(2):109-13.

 

41. Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 1998;114:1236-1258.

 

42. Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arc Intern Med 1995;155(18):1965-70.

 

43. PI interview (Richard Moore), November 2000.

 

44. Chaisson RE, Gallant JE, Keruly JC, et al. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12(1):29-33.

 

45. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(1, suppl.):S38-S41.

 

46. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124(7):633-42.

 

47. Gallant JE, Chaisson RE, Keruly JC, et al. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naïve patients. AIDS 1999;13(2):225-29.

 

48. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999;13(8):963-69.

 

49. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14(3):223-31.

 

50. Fortgang IS, Moore RD. Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8(4):365-72.

 

51. Gallant JE, McAvinue SM, Moore RD, et al. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 1995;107(4):1018-23.

 

52. Stanton DL, Wu AW, Moore RD, et al. Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr 1994;7(10):1050-56.

 

53. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330(11):763-68.

 

54. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333(12):751-56.

 

55. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virological failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.

 

56. Celentano DD, Vlahor D, Cohn S, et al. Self-reported antiretroviral therapy for HIV infection among injection drug users. JAMA 1998;280:544-46.

 

57. Interviews with PI (Judith Garrard) and health plan representative, November 2000.

 

58. Garrard J. Health related quality of life [manuscript].

 

59. Garrard J, Rolnick SJ, Nitz NM, et al. Clinical detection of depression among community-based elderly people with self-reported symptoms of depression. J Gerontol A Biol Sci Med Sci 1998;53(2):M92-101.

 

60. Leibson CL, Garrard J, Nitz N, et al. The role of depression in the association between self-rated physical health and clinically defined illness. Gerontologist 1999;39(3):291-98.

 

61. PI Interview (G. Thomas Strickland), September 2000.

 

62. Interview with medical director Delmarva Health Plan, September 2000.

 

63. Delmarva Health Plan Provider Bulletin, May 2000.

 

64. Coyle BS, Strickland GT, Liang YY, et al. The public health impact of Lyme disease in Maryland. J of Infect Dis 1996;273:1260-62.

 

65. Strickland T. Patient outcomes with antibiotic therapy of Lyme disease: Final report 1999. Rockville (MD):2000. Agency for Health Care Policy and Research; NTIS Accession No. PB 2000-106707.

 

66. Fix AD, Strickland T, Grant J. Tick bites and Lyme disease in an endemic setting. JAMA 1998;279(3):206-10.

 

67. Strickland GT, Karp AC, Mathews A, et al. Utilization and cost of serologic tests for Lyme disease in Maryland. J Infect Dis 1997;176(3):819-21.

 

68. Fix AD, Pena CA, Strickland GT. Racial differences in reported Lyme disease incidence. Am J Epidemiol 2000 Oct;152(8):756-59.

 

69. Stergachis AS. Pharmaceutical care and pediatric asthma outcomes: Final report 1998. Rockville (MD): Agency for Health Care Policy and Research; NTIS Accession No. PB 2000-101828.

 

70. Chewning B, Bell C, Nowlin N, et al. A comparison of AIMS2 and SF-36 health quality of life measures [abstract]. Arthritis Rheum 1994;37(9, suppl.):S225.

 

71. Chewning BA. Pharmaceutical care outcomes—The patient role: Final report 1998. Rockville (MD):2001. Agency for Health Care Policy and Research; NTIS Accession No. PB 2001-107624INM.

 

72. PI Interview (Betty Chewning), September 2000.

 

73. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 Sep;37(9):846-57.

 

74. Platt R. Use of record linkage to study outcomes of drug therapy: Final report 1998. Rockville (MD):1999. Agency for Health Care Policy and Research; NTIS Accession No. PB 99-124042INM

 

75. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996;124(9):792-802.

 

76. Wu AW, Hays RD, Kelly S, et al. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997;6(6):531-54.

 

77. Hanlon JT, Landerman LR, Wall WE, et al. Is medication use by community-dwelling elderly people influenced by cognitive function? Age Ageing 1996;25:190-96.

 

78. Schmader KE, Hanlon JT, Fillenbaum GG, et al. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing 1998;27(4):493-501.

 

79. Goldstein MK, Clarke AE, Michelson D, et al. Developing and testing a multimedia presentation of a health-state description. Med Decis Making 1994;14(4):336-44.

 

80. Lenert LA, Michelson D, Flowers C, et al. IMPACT: an object-oriented graphical environment for construction of multimedia patient interviewing software. Proc Annu Symp Comput Appl Med Care 1995;319-23.

 

81. Clarke AE, Goldstein MK, Michelson D, et al. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res 1997 Mar;6(2):169-84.

 

82. Lenert LA, Cher DJ, Goldstein MK, et al. The effect of search procedures on utility elicitations. Med Decis Making 1998 Jan-Mar;18(1):76-83.

 

83. Gardner LB. Pharmaceutical use and cost among insured elderly: Abstract, Executive Summary, and Final Report. 1996. Berkeley: Western Consortium for Public Health; NTIS Accession No. PB 97-165856.

 

84. PI Interview (Laura Gardner), September 2000.

 

85. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998 Nov 4;280(17):1490-96.

 

86. Testa MA, Turner RR, Simonson DC, et al. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. Gastrointestinal Therapeutic System. J Hypertens 1998 Dec;16(12 Pt 1):1839-47.

 

87. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care 1998 Dec;21(suppl 3):C44-52.

 

88. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life association with zidovundine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med 1994;330(11):738-43.

 

89. Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J Nutr 1999 Jan;129(suppl.):282S-289S.

 

90. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs—Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332(17):1125-31.

 

91. Anderson RB, Testa MA. Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Info J 1994;28:89-114.

 

92. Merliss M. Explaining the growth in prescription drug spending: a review of recent studies. Institute for Health Policy Solutions. In: Conference binder for Pharmaceutical Pricing Practices, Utilization and Costs, August 2000, sponsored by the Office of the Assistant Secretary for Planning and Evaluation, HHS.

 

93. Thomas CP and Ritter G. Drug utilization trends by therapeutic class Schneider Health Policy, Brandeis University Heller Graduate School. In: Conference binder for Pharmaceutical Pricing Practices, Utilization and Costs, August 2000, sponsored by the Office of the Assistant Secretary for Planning and Evaluation, HHS.

 

94. Stuart B and Briesacher B. Medication decisions—Right and wrong. The Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy. In: Conference binder for Pharmaceutical Pricing Practices, Utilization and Costs, August 2000, sponsored by the Office of the Assistant Secretary for Planning and Evaluation, HHS.

 

95. Kreling DH. Cost control for prescription drug programs: pharmacy benefit manager (pbm) efforts, effects and implications. In: Conference binder for Pharmaceutical Pricing Practices, Utilization and Costs, August 2000, sponsored by the Office of the Assistant Secretary for Planning and Evaluation, HHS.

Return to Contents

Current as of October 2001
Internet Citation: Outcomes of Pharmaceutical Outcomes Research: Impact of Studies Funded. October 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/research/findings/final-reports/pharmaceutical-outcomes-research/references.html